A Phase 2 interventional study of LY3502970 and Dulaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 44 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 2, and was the 2nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Massachusetts General Hospital
Ages 18–79
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 2 started in 2021.
This study's enrollment of 383 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 546 across the 15 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 78th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2021, is one of 34 in phase 2, and was the 177th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing orforglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
Drug: LY3502970
Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
Drug: LY3502970
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
Drug: LY3502970
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Drug: LY3502970
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Drug: LY3502970
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Drug: LY3502970
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Drug: LY3502970
Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
Drug: Dulaglutide
Participants received matching placebo.
Drug: Placebo
Administered orally
Administered subcutaneously
Administered orally
Administered subcutaneously
Change From Baseline in HbA1c in LY3502970 as Compared to Placebo
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 26
Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 26
Percentage of Participants With HbA1c ≤ 6.5%
Percentage of Participants with HbA1c ≤ 6.5%. Odds ratio was calculated using logistic regression model.
Time frame: Week 26
Percentage of Participants With HbA1c <7.0%
Percentage of Participants with HbA1c \<7.0%. Odds ratio was calculated using logistic regression model.
Time frame: Week 26
Change From Baseline in Fasting Serum Glucose
Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, 8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 26
Change From Baseline in Body Weight
LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 26
Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970
PK: Steady State AUC of LY3502970
Time frame: Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
| Milestone | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Started | 55 | 51 | 56 | 47 | 27 | 34 | 31 | 32 | 50 |
| Received at least one dose of study drug | 55 | 51 | 56 | 47 | 27 | 34 | 31 | 32 | 50 |
| Completed | 51 | 47 | 50 | 42 | 25 | 30 | 29 | 29 | 49 |
| Not completed | 4 | 4 | 6 | 5 | 2 | 4 | 2 | 3 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 1 | 0 | 2 | 1 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 3 | 1 | 1 | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Patient decision due to changes in personal life | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant was unresponsive and too far out of window to resume treatment | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision due to inadvertent enrollment | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant decided to discontinue treatment and only return for single final visit | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site terminated participant due to sponsor directions | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percentage of HbA1c | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c in LY3502970 as Compared to Placebo | -1.19 ± 0.137 | -1.91 ± 0.133 | -1.79 ± 0.149 | -2.03 ± 0.127 | -2.10 ± 0.124 | -0.43 ± 0.128 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percentage of HbA1c | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide | -1.19 ± 0.137 | -1.91 ± 0.133 | -1.79 ± 0.149 | -2.03 ± 0.127 | -2.10 ± 0.124 | -1.10 ± 0.131 |
Percentage of Participants with HbA1c ≤ 6.5%. Odds ratio was calculated using logistic regression model.
| Percentage of participants | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With HbA1c ≤ 6.5% | 45.30 | 70.73 | 80.12 | 79.39 | 83.52 | 14.56 | 41.04 |
Percentage of Participants with HbA1c \<7.0%. Odds ratio was calculated using logistic regression model.
| Percentage of participants | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With HbA1c <7.0% | 65.17 | 78.92 | 91.24 | 92.75 | 95.76 | 24.27 | 64.06 |
Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, 8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| milligrams per deciliter (mg/dL) | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose | -32.6 ± 4.14 | -53.7 ± 3.92 | -52.2 ± 4.49 | -53.9 ± 3.79 | -55.9 ± 3.69 | -11.1 ± 3.90 | -33.2 ± 3.91 |
LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| kilograms (kg) | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight | -3.7 ± 0.79 | -6.5 ± 0.76 | -9.7 ± 0.85 | -9.5 ± 0.73 | -10.1 ± 0.71 | -2.2 ± 0.74 | -3.9 ± 0.76 |
PK: Steady State AUC of LY3502970
| nanogram *hour per milliliter (ng*h/mL) | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970 | 364 ± 38.7 | 1020 ± 63.5 | 1500 ± 84.5 | 1830 ± 94.6 | 2430 ± 39.8 | 2230 ± 80.4 | 2550 ± 55.3 |
Collected over Baseline Through Safety Follow-Up (Up To Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/55 (1.8%) | 3/55 (5.5%) | 25/55 (45.5%) |
| 3 mg LY3502970 | 0/51 (0%) | 3/51 (5.9%) | 34/51 (66.7%) |
| 12 mg LY3502970 | 0/56 (0%) | 1/56 (1.8%) | 40/56 (71.4%) |
| 24 mg LY3502970 | 0/47 (0%) | 5/47 (10.6%) | 32/47 (68.1%) |
| 36 mg LY3502970 - 1 | 0/27 (0%) | 1/27 (3.7%) | 21/27 (77.8%) |
| 36 mg LY3502970 - 2 | 0/34 (0%) | 1/34 (2.9%) | 18/34 (52.9%) |
| 45 mg LY3502970 - 1 | 0/31 (0%) | 0/31 (0%) | 21/31 (67.7%) |
| 45 mg LY3502970 - 2 | 0/32 (0%) | 1/32 (3.1%) | 23/32 (71.9%) |
| 1.5 mg Dulaglutide | 0/50 (0%) | 1/50 (2%) | 23/50 (46%) |
| Event | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Ischaemic strokeNervous system disorders | 1/55 | 0/51 | 0/56 | 0/47 | 1/27 | 0/34 | 0/31 | 0/32 | 0/50 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/55 | 0/51 | 0/56 | 0/47 | 0/27 | 0/34 | 0/31 | 1/32 | 0/50 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/55 | 0/51 | 0/56 | 0/47 | 0/27 | 1/34 | 0/31 | 0/32 | 0/50 |
| Urethral haemorrhageRenal and urinary disorders | 0/55 | 0/51 | 0/56 | 0/47 | 0/27 | 1/34 | 0/31 | 0/32 | 0/50 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/55 | 0/51 | 0/56 | 1/47 | 0/27 | 0/34 | 0/31 | 0/32 | 0/50 |
| Pancreatitis acuteGastrointestinal disorders | 0/55 | 0/51 | 0/56 | 1/47 | 0/27 | 0/34 | 0/31 | 0/32 | 0/50 |
| PylorospasmGastrointestinal disorders | 0/55 | 0/51 | 0/56 | 1/47 | 0/27 | 0/34 | 0/31 | 0/32 | 0/50 |
| Varices oesophagealGastrointestinal disorders | 0/55 | 0/51 | 0/56 | 1/47 | 0/27 | 0/34 | 0/31 | 0/32 | 0/50 |
| AppendicitisInfections and infestations | 0/55 | 0/51 | 0/56 | 1/47 | 0/27 | 0/34 | 0/31 | 0/32 | 0/50 |
| DehydrationMetabolism and nutrition disorders | 0/55 | 0/51 | 0/56 | 1/47 | 0/27 | 0/34 | 0/31 | 0/32 | 0/50 |
| Event | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide |
|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/55 | 12/51 | 21/56 | 16/47 | 10/27 | 9/34 | 9/31 | 8/32 | 9/50 |
| VomitingGastrointestinal disorders | 1/55 | 3/51 | 12/56 | 13/47 | 9/27 | 7/34 | 11/31 | 7/32 | 4/50 |
| DiarrhoeaGastrointestinal disorders | 4/55 | 11/51 | 9/56 | 7/47 | 7/27 | 2/34 | 9/31 | 9/32 | 6/50 |
| ConstipationGastrointestinal disorders | 1/55 | 7/51 | 7/56 | 6/47 | 6/27 | 1/34 | 1/31 | 4/32 | 0/50 |
| EructationGastrointestinal disorders | 0/55 | 4/51 | 2/56 | 3/47 | 5/27 | 3/34 | 2/31 | 1/32 | 1/50 |
| HeadacheNervous system disorders | 0/55 | 7/51 | 2/56 | 2/47 | 0/27 | 1/34 | 2/31 | 4/32 | 0/50 |
| DyspepsiaGastrointestinal disorders | 2/55 | 6/51 | 4/56 | 3/47 | 3/27 | 2/34 | 2/31 | 2/32 | 1/50 |
| FlatulenceGastrointestinal disorders | 1/55 | 0/51 | 0/56 | 4/47 | 3/27 | 1/34 | 1/31 | 1/32 | 1/50 |
| Weight decreasedInvestigations | 0/55 | 0/51 | 2/56 | 2/47 | 3/27 | 2/34 | 1/31 | 0/32 | 0/50 |
| Decreased appetiteMetabolism and nutrition disorders | 0/55 | 3/51 | 3/56 | 2/47 | 2/27 | 1/34 | 2/31 | 3/32 | 2/50 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 58.30 ± 9.52 | 59.00 ± 9.43 | 57.40 ± 9.23 | 60.50 ± 9.11 | 59.20 ± 9.07 | 60.10 ± 9.37 | 58.10 ± 10.63 | 58.90 ± 8.18 | 58.80 ± 10.19 | 58.90 ± 9.40 |
| Sex: Female, Male(Participants) | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 27 | 25 | 20 | 17 | 9 | 16 | 10 | 13 | 20 | 157 |
| Male | 28 | 26 | 36 | 30 | 18 | 18 | 21 | 19 | 30 | 226 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 7 | 15 | 5 | 6 | 7 | 7 | 6 | 7 | 74 |
| Not Hispanic or Latino | 41 | 44 | 41 | 42 | 21 | 27 | 24 | 26 | 43 | 309 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 4 |
| Asian | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 5 | 2 | 0 | 0 | 2 | 3 | 4 | 22 |
| White | 50 | 47 | 49 | 43 | 25 | 33 | 29 | 28 | 44 | 348 |
| More than one race | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hungary | 10 | 8 | 9 | 8 | 3 | 6 | 6 | 4 | 9 | 63 |
| Poland | 11 | 13 | 11 | 10 | 6 | 9 | 7 | 6 | 12 | 85 |
| Slovakia | 10 | 8 | 10 | 9 | 5 | 5 | 5 | 6 | 7 | 65 |
| United States | 24 | 22 | 26 | 20 | 13 | 14 | 13 | 16 | 22 | 170 |
| Hemoglobin A1c (HbA1c)(Percentage of HbA1c) | Placebo | 3 mg LY3502970 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 - 1 | 36 mg LY3502970 - 2 | 45 mg LY3502970 - 1 | 45 mg LY3502970 - 2 | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 8.1 ± 0.9 | 8.0 ± 0.8 | 8.2 ± 0.9 | 8.2 ± 0.9 | 8.0 ± 0.7 | 8.1 ± 0.8 | 8.3 ± 1.0 | 8.0 ± 0.8 | 8.0 ± 0.7 | 8.1 ± 0.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2021 to primary completion in Sep 2022, 12 months.
Results were first posted in Oct 2023, 1 year after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 12 months is close to that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron